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Abstract
Aims/hypothesis The aim of this study was to assess whether
or not a theory-based behaviour change intervention delivered
by trained and quality-assured lifestyle facilitators can achieve
and maintain improvements in physical activity, dietary
change, medication adherence and smoking cessation in peo-
ple with recently diagnosed type 2 diabetes.
Methods An explanatory randomised controlled trial was con-
ducted in 34 general practices in Eastern England (Anglo–
Danish–Dutch Study of Intensive Treatment in People with
Screen Detected Diabetes in Primary Care-Plus [ADDITION-
Plus]). In all, 478 patients meeting eligibility criteria (age 40 to
69 years with recently diagnosed screen or clinically detected
diabetes) were individually randomised to receive either
intensive treatment (n=239) or intensive treatment plus a
theory-based behaviour change intervention led by a facilitator
external to the general practice team (n=239). Randomisation
was central and independent using a partial minimisation pro-
cedure to balance stratifiers between treatment arms. Facilita-
tors taught patients skills to facilitate change in and mainte-
nance of key health behaviours, including goal setting, self-
monitoring and building habits. Primary outcomes included
physical activity energy expenditure (individually calibrated
heart rate monitoring and movement sensing), change in
objectively measured fruit and vegetable intake (plasma
vitamin C), medication adherence (plasma drug levels) and
smoking status (plasma cotinine levels) at 1 year. Measure-
ments, data entry and laboratory analysis were conducted
with staff unaware of participants’ study group allocation.
Results Of 475 participants still alive, 444 (93%; intervention
group 95%, comparison group 92%) attended 1-year follow-
up. There were no significant differences between groups in
physical activity (difference: +1.50 kJ kg−1 day−1; 95% CI
−1.74, 4.74), plasma vitamin C (difference: −3.84 μmol/l;
95% CI −8.07, 0.38), smoking (OR 1.37; 95% CI 0.77,
2.43) and plasma drug levels (difference in metformin levels:
−119.5 μmol/l; 95% CI −335.0, 95.9). Cardiovascular risk
factors and self-reported behaviour improved in both groups
with no significant differences between groups.
Conclusions/interpretation For patients with recently diag-
nosed type 2 diabetes receiving intensive treatment in UK
primary care, a facilitator-led individually tailored behaviour
change intervention did not improve objectively measured
health behaviours or cardiovascular risk factors over 1 year.
Trial registration ISRCTN99175498
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Abbreviations
ADDITION Anglo–Danish–Dutch Study of Intensive
Treatment in People with Screen Detected
Diabetes in Primary Care
CARE Consultation and Relational Empathy
CVD Cardiovascular disease
DESMOND Diabetes Education and Self-Management
for Ongoing and Newly Diagnosed
Diabetes
Early ACTID Early Activity in Diabetes
EQ-5D EuroQol 5-D
Look-AHEAD Action for Health Diabetes
MARS Medication Adherence Report Schedule
PAEE Physical activity energy expenditure
SF-36 Short-Form 36
TPB Theory of planned behaviour
UKPDS UK Prospective Diabetes Study
Introduction
Well-organised care, including regular recall and review of
patients, prompting of doctors, feedback on goal attainment,
and continuing medical education and guidelines, are associ-
ated with reductions in risk factors among people with type 2
diabetes [1, 2]. In addition, intensive pharmacological treat-
ment of risk factors can reduce cardiovascular morbidity and
mortality [3, 4]. However, these benefits depend on people
with diabetes taking their medication as prescribed, eating a
healthy diet, being physically active on a regular basis and
avoiding smoking.
There is some evidence that patient education, training
patients in self-management and using interventions incorpo-
rating well-specified behaviour change techniques can be
effective, at least in the short term [5]. However, only aminority
of people with type 2 diabetes in the UK have attended a
structured education programme to assist with behaviour
change, and where attendance has occurred the effectiveness
of the programme in practice is largely uncertain [6].
The Early Activity In Diabetes (Early ACTID: ISRCT
N92162869) and Action for Health Diabetes (Look-AHEAD:
NCT00017953) trials have demonstrated beneficial effects on
cardiovascular risk factors of adding intensive lifestyle
interventions to the primary care of diabetes patients [7, 8].
These studies were selective in their behavioural focus. Many
previous studies have been conducted in research clinics or
specialist settings and have not clearly characterised the compar-
ison condition. Behavioural interventions and their hypothesised
mechanisms of action are rarely clearly specified and the deliv-
ery of the intervention is not often assessed. Most trials have
relied on self-reported measures of behaviour, which are impre-
cise and subject to recall bias, and do not assess adherence to
medication. This limits evaluation of the effects of behavioural
interventions independent of organisational and pharmacological
components, and cannot inform subsequent integration of the
most effective components into routine practice.
We aimed to address these uncertainties in the Anglo–
Danish–Dutch Study of Intensive Treatment in People with
Screen Detected Diabetes in Primary Care-Plus (ADDITION-
Plus) trial by evaluating the effect of a theory-based behaviour
change intervention delivered by trained and quality-assured
lifestyle facilitators, external to the primary care team, on
objectively measured health behaviours (physical activity, diet
change, medication adherence and smoking) among people
with recently diagnosed type 2 diabetes receiving intensive
general practice care [9].
Methods
Study design
The study design and rationale have been reported previously
(2002–2007) [9]. Patients were recruited from 34 general prac-
tices in the East of England. The majority of practices (n=26)
were participating in the intensive treatment arm of the
ADDITION-Cambridge trial of treatment of people with dia-
betes detected by screening (ISRCTN86769081) [10]. A further
eight practices were recruited to increase the participation of
recently clinically diagnosed patients (Fig. 1). Eligibility criteria
were initially assessed by general practice staff and included
age 40–69 years with type 2 diabetes following screening in the
ADDITION study or clinical diagnosis during the previous
3 years. Exclusion criteria included patients who had a psychot-
ic illness or an illness with a likely prognosis of <1 year and
women who were pregnant or lactating. Of 425 eligible screen-
detected patients and 684 patients clinically diagnosed within
the previous 3 years, 239 from each group agreed to be indi-
vidually randomised to receive intensive treatment alone (com-
parison group) or in conjunction with a facilitator-led behaviour
change intervention (intervention group).
Randomisation
Randomisation was central using a partial minimisation pro-
cedure to balance stratifiers (age, sex and general practice; and
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within screen-detected and clinically diagnosed subgroups:
BMI, self-reported smoking and medication adherence [11])
between the arms [9]. Randomisation was undertaken inde-
pendently of study coordination or knowledge of or contact
with participants or their data, other than the stratifiers. Ethical
approval was obtained from the EasternMultiCentre Research
Ethics Committee (reference no. 02/5/54). All participants
provided written informed consent.
Intervention
Comparison group: intensive treatment A number of features
were added to routine multidisciplinary primary care of dia-
betes to achieve intensive treatment in both trial groups as
previously described [9, 10] (see Electronic Supplementary
Material [ESM] for further details).
Intervention group: intensive treatment plus facilitator-led
behaviour change intervention Participants in the intervention
group received intensive treatment (described above) plus
a facilitator-led, individually tailored behaviour change
intervention, based on psychological theory and evidence.
Full details of the intervention have been described pre-
viously (see ESM) [9]. In brief, the intervention was
delivered by three female trained lifestyle facilitators,
who were not part of the general practice team. The
facilitators used detailed protocols to guide each contact
with the participant and received ongoing supervision
and feedback from a clinical psychologist. The behav-
iours targeted in the intervention were physical activity,
dietary intake, medication adherence and smoking ces-
sation. Facilitators taught patients a range of self-
regulatory skills to achieve behaviour change and main-
tenance over time, supported by a manual describing the
skills. The intervention was delivered over 1 year at the
participants’ surgeries and included a 1 h introductory
meeting followed by six 30 min meetings and four brief
phone calls.
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Primary endpoint analysed:
218 participants with physical activity data
218 participants with dietary intake data
174 participants with medication 
adherence data
197 participants with smoking status data
Participant status at 1 year follow-up:
1 (0.4%) died 
220 (92%) attended 1 year visit at clinical research 
facility 
4 (2%) returned questionnaires only
13 (5%) refused to attend 1 year follow-up
1 (0.4%) unable to contact
Participant status at 1 year follow-up:
2 (0.8%) died
224 (94%) attended 1 year visit at clinical 
research facility
5 (2%) returned questionnaires only
8 (3%) refused to attend 1 year follow-up
Total population available for 
individual randomisation
n=478
26 practices nested within the intensive treatment 
arm of the ADDITION-Cambridge trial, with 
n=425 screen-detected type 2 diabetes patients 
invited to join ADDITION-Plus
239 patients agree to be randomised 
into ADDITION-Plus
27 practices (19 ADDITION-Cambridge, 8 non-
ADDITION practices), with n=684 type 2 
diabetes patients diagnosed within the previous 
3 years invited to join ADDITION-Plus
239 patients agree to be randomised 
into ADDITION-Plus
Allocated to comparison group (n=239)
118 screen detected patients
121 patients diagnosed in previous 3 years
Allocated to intervention group (n=239)
121 screen detected patients
118 patients diagnosed in previous 3 years
Received intervention
223 patients received the intervention
(119 screen-detected and 104 recently 
diagnosed)
Primary endpoint analysed:
212 participants with physical activity data
216 participants with dietary intake data
152 participants with medication 
adherence data
174 participants with smoking status data
Fig. 1 Study design and
participant flow in the
ADDITION-Plus trial
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Measurements and endpoints
Baseline and 1 year measurements were undertaken at outpa-
tient clinical research facilities by trained staff following stan-
dard operating procedures. Double data entry of anthropomet-
ric and questionnaire measures was undertaken by indepen-
dent agencies. Measurements, data entry and laboratory analy-
sis were conducted with staff unaware of participants’ study
group allocation.
Primary outcomes
Objectively measured health behaviours Physical activity was
assessed at 1 year using a combined heart rate and movement
sensor (Actiheart, CamNtech, Cambridge, UK), which partic-
ipants were advised to wear continuously for at least 4 days
[12]. A graded treadmill walk test was used to individually
calibrate heart rate [13] and to estimate cardiorespiratory
fitness by extrapolation of the heart rate/oxygen consumption
relationship to age-predicted maximal heart rate [14]. Time-
series data were pre-processed [15] and summarised into
physical activity energy expenditure (PAEE, kJ kg−1 day−1)
[16]. Data from participants without a treadmill test (n=79)
were processed using an adjusted group calibration equation
based on treadmill tests.
Intake of fruit and vegetables was assessed at baseline and
1 year by measurement of plasma vitamin C levels using a
Fluoroskan Ascent FL fluorometer (Fisher Scientific UK,
Loughborough, UK) [17]. Smoking status was assessed at
1 year by analysis of plasma cotinine levels using an Immulite
Nicotine metabolite solid phase competitive chemilumines-
cent immunoassay (Siemens Healthcare Diagnostics, Llanber-
is, UK) and self-report. Self-reported non-smokers with cotin-
ine levels exceeding ≥15 ng/ml (n=12) were re-classified as
smokers [18]. Participants were advised to take their medica-
tion as usual on the day of testing. Medication adherence was
assessed at 1 year follow-up by measurement of plasma con-
centrations of the three drugs that provided maximum partic-
ipant coverage (metformin, simvastatin and atorvastatin)
using liquid-chromatography–mass-spectrometry after pro-
tein precipitation extraction [9].
Secondary outcomes
Self-reported health behaviours Physical activity, dietary in-
take and adherence to hypoglycaemic and other medication
were assessed using the previously validated EPIC–Norfolk
Physical Activity Questionnaire [19], Food Frequency Ques-
tionnaire [20] and theMedication Adherence Report Schedule
(MARS) [11], respectively. At 1 year, participants were asked
whether or not they had made changes to their physical
activity and dietary behaviours in the preceding 12 months.
Modelled risk of cardiovascular disease This was calculated
for individuals without a prior cardiovascular disease (CVD)
event using the UK Prospective Diabetes Study (UKPDS)
model [21].
Biochemical and clinical measures Biochemical measures
were assessed using standard assays (ESM) [9]. Detailed
measurement protocols for blood pressure, height, weight,
waist circumference and body fat percentage have been de-
scribed previously [9]. Angina was assessed using the Rose
angina questionnaire [22]. Neuropathy was evaluated using an
adapted version of the Michigan Neuropathy Screening In-
strument [23].
Functional status, healthy utility, anxiety, well-being, quality
of life, treatment satisfaction and relational empathy The
following generic and disease-specific instruments were used:
Short-Form 36 (SF-36) [24], EuroQol (EQ-5D) [25], the short
form of the state scale of the Spielberger State-Trait Anxiety
Inventory [26], diabetesWell-Being Questionnaire [27], Audit
of Diabetes Dependent Quality of Life [27] and Diabetes
Treatment Satisfaction Questionnaire [27]. All patients com-
pleted the Consultation and Relational Empathy (CARE)
measure in relation to the general practitioner and practice
nurse [28], and a question concerning satisfaction with diabe-
tes services. In addition, participants in the intervention group
completed the CARE measure in relation to the lifestyle
facilitator.
Beliefs about behaviour change, illness perceptions and
habit A questionnaire developed according to the theory of
planned behaviour (TPB) model [29, 30] assessed selected
cognitions about becoming more physically active, eating a
lower-fat diet, taking medication and smoking cessation: in-
tention, perceived behavioural control and behavioural be-
liefs. Full details are reported elsewhere [9]. Participants also
completed the consequences and treatment control subscales
(11 items) of the Illness Perception Questionnaire-Revised
[31, 32] and a nine-item closed-response questionnaire cover-
ing basic knowledge of diabetes and its management [33]. At
1 year, participants were asked to write down the most impor-
tant change they had made in their physical activity and
dietary intake [34]. Cronbach’s alpha for TPB measures and
the Illness Perception Questionnaire measures demonstrated
high internal consistency. However, internal consistency was
low (0.55) for diabetes treatment control and perceived be-
havioural control in relation to stopping smoking.
Statistical analysis
We planned to recruit 500 participants. Follow-up of 400
individuals would provide 80% power at the 5% level of
significance to detect between-arm differences of
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0.017 kJ kg−1 min−1 in PAEE (anticipating a mean [SD] of
0.078 [0.058]kJ kg−1 min−1) [35], 4.0 μmol/l in change from
baseline in plasma vitamin C adjusted further for baseline
(based on a mean [SD] of 53 [19] μmol/l and test–retest
correlation of 0.67 [36]) and 9.5% in smoking prevalence
(control prevalence 17.9%).
The effectiveness of the intervention on primary outcomes
was assessed using between-arm intention-to-treat analysis,
using linear and logistic regression for continuous and binary
outcomes, respectively. Continuous outcomes adjusted for
baseline where measured. Participants with missing baseline
values were retained in the analysis by using the missing
indicator method [37]. Effect sizes were reported with 95%
CIs. Statistical significance was set at p<0.05. Continuous
outcomes indicating non-normality or skewness (simvastatin,
atorvastatin, triacylglycerol, alanine aminotransferase and
UKPDS risk score) were natural log-transformed before
analysis and their CIs were shown on the log-scale. Where
non-normality could not be resolved by log-transformation,
95% CIs were estimated using semi-parametric bias corrected
and accelerated bootstrap regression with 1,999 resamples.
We conducted a per protocol analysis of each primary out-
come, in which the per protocol population comprised
comparison-arm participants and those intervention-arm par-
ticipants who attended the introductory and initial three core-
intervention sessions. Sensitivity analysis was undertaken to
assess the impact of excluding participants with missing pri-
mary outcome data. Rubin’s multiple imputation method with
30 multiple imputation datasets [38] was used together with
two contrasting scenarios for the intervention effect in exclud-
ed participants. The first optimistically assumed that excluded
participants achieved the same full intervention effect as ob-
served in participants with the outcome data, and the second
pessimistically assumed that no intervention effect was
achieved. Subgroup analyses were confined to the comparison
of intervention effects on primary outcomes by mode of
diagnosis (screen-detected or recently diagnosed).
Results
Figure 1 shows the trial profile. Participating practices were
largely comparable with the average English practice in terms
of list size, diabetes prevalence and general practice/nurse
whole-time equivalents (data taken from the National Primary
Care Database; www.population-health.manchester.ac.uk/
primarycare/npcrdc-archive/archive/ProjectDetail.cfm/ID/10.
htm). However, the median (interquartile range) Index of
Multiple Deprivation score for ADDITION-Plus practices
(11.7 [6.6–15.5]) suggested that they served less deprived
communities than the average English practice (21.2 [12.2–
36.1]) (data taken from the UK National Primary Care Data-
base). Four hundred and seventy-eight eligible participants
were recruited to the study (intervention group n=239; com-
parison group n=239) and attended baseline measurement.
Baseline characteristics were similar in the two trial groups
(Table 1). The majority of ADDITION-Plus participants were
white men with a mean age of 60 years. In all, 51% of
participants were in full- or part-time employment, and 62%
had attended full-time education after the age of 16 years.
There was one death in the comparison group and two deaths
in the intervention group within 13 months of recruitment. Of
those still alive, 444/475 (93%; intervention group: 95%,
comparison group: 92%) returned for follow-up health assess-
ment after a mean of 1.1 years (SD 0.2). There was no
significant difference in baseline characteristics between those
who attended follow-up health assessment and those who did
not (data not shown).
Objectively measured health behaviours
Table 2 shows the outcomes of objectively measured health
behaviours. PAEE levels were similar in both groups at 1 year.
We observed small increases in plasma vitamin C levels in
both groups over 12 months, with levels approximating na-
tional trends (National Diet and Nutrition Survey 2002 [39])
and not significantly differing by group. The proportion of
smokers was similar in the intervention and comparison
groups at 1 year, reflecting national smoking rates [40]. There
were no differences between groups in the proportion of
patients prescribed metformin, simvastatin and atorvastatin
(data not shown), the mean prescribed total daily dose of each
drug (data not shown) and the plasma drug levels.
Self-reported health behaviours
Participants reported increases in levels of total physical ac-
tivity and consumption of fruit, vegetables and fibre, and
reduction in consumption of fat and alcohol over 1 year, with
no significant difference between groups (Table 3). There was
little change in the proportion smoking with no significant
Table 1 Baseline characteristics of ADDITION-Plus trial participants
(n=478)
Participant characteristics Comparison group
(n=239)
Intervention group
(n=239)
Mean age (SD), years 59.8 (7.5) 59.5 (7.5)
Men 148 (61.9) 150 (62.8)
White ethnicity 234 (97.9) 232 (97.1)
In full- or part-time
employment
122/238 (51.3) 123/239 (51.5)
Full-time education after
16 years of age
145/236 (61.4) 146/236 (61.9)
Values are n (%) unless specified
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Table 2 Objectively measured health behaviours by study group and between-group differences at 1 year in the ADDITION-Plus trial
Health behaviours Comparison group Intervention group Difference between groups (95% CI) p value
PAEE, kJ kg−1 day−1a 33.7 (15.9) (N=212) 35.2 (18.2) (N=218) +1.50 (−1.74, 4.74) 0.36
Plasma vitamin C, μmol/l 56.2 (25.1) (N=216) 53.4 (25.0) (N=218) −3.84 (−8.07, 0.38)b 0.07
Smoking, %; cotinine validated (n/N) 13.2 (23/174) 17.3 (34/197) 1.37c (0.77, 2.43) 0.28
Drug plasma level, μmol/l
Metformin 1,310.0 (741.7) (N=82) 1,190.5 (725.6) (N=100) −119.5 (−335.0, 95.9) 0.28
Log simvastatind −1.07 (1.73) (N=30) −1.43 (1.45) (N=42) −0.36 (−1.10, 0.39) 0.35
Log atorvastatind 1.07 (1.01) (N=40) 0.91 (1.02) (N=32) −0.16 (−0.63, 0.32) 0.52
Values are mean SD unless otherwise stated; N is the number with data available
a Physical activity is individually calibrated where available (n=351), otherwise group calibrated (n=79)
b Difference between groups is adjusted for baseline values
c Results are expressed as ORs
d Results are expressed on the natural log-scale since original variable showed substantial skewness
Table 3 Baseline and 1 year follow-up self-reported behaviours by study group and between-group differences in the ADDITION-Plus trial
Self-reported behaviour Comparison group Intervention group Adjusted difference between
groups (95% CI)
Baseline 1 year Baseline 1 year
Physical activity
Total physical activity, MET h/week 78.6 (48.0) 80.1 (49.5) 90.0 (55.1) 95.2 (55.7) +7.51 (−0.009, 15.0)
Recreational activity, h/week 9.63 (9.81) 10.4 (10.6) 12.0 (13.0) 13.1 (12.9) +1.46 (−0.40, 3.34)a
Vigorous activity, h/week 1.03 (2.41) 1.04 (2.81) 1.33 (3.59) 1.42 (3.39) +0.23 (−0.32, 0.72)a
Time spent in sedentary activity, h/week 38.7 (19.6) 36.4 (17.7) 35.3 (15.5) 33.4 (16.3) −0.60 (−2.57, 1.38)
Television viewing, h/week 24.4 (12.8) 23.9 (11.7) 24.0 (10.2) 23.4 (10.3) −0.20 (−1.49, 1.10)
Proportion reporting change in physical
activity at 1 year, %
– 41.0 (91/222) – 74.9 (170/227) 4.29 (2.87, 6.42)b
Diet
Total fat, g/day 68.7 (30.3) 60.3 (23.3) 68.3 (29.6) 60.6 (22.2) +0.41 (−3.11, 3.94)
Fat as percentage of energy, % 32.0 (6.2) 31.2 (6.0) 31.3 (5.7) 30.4 (5.9) −0.45 (−1.41, 0.51)
Polyunsaturated:saturated fat ratio 0.58 (0.23) 0.67 (0.27) 0.62 (0.28) 0.68 (0.26) −0.01 (−0.06, 0.03)
Fibre, g/day 18.6 (7.3) 19.0 (7.3) 18.6 (7.2) 19.8 (7.0) 0.82 (−0.31, 1.95)
Plasma vitamin C, mg/day 147.4 (71.2) 145.5 (66.0) 141.0 (72.2) 146.2 (66.5) 3.89 (−6.62, 14.40)
Total energy, kJ 7,966 (2,628) 7,200 (2,092) 8,099 (2,757) 7,446 (2,110) 188.0 (−136.5, 512.5)
Fruit food group (11 items), g/day 277 (197) 312 (222) 266 (198) 312 (212) 4.89 (−31.2, 41.2)a
Vegetable food group (19 items), g/day 237 (128) 246 (148) 231 (161) 247 (135) 4.76 (−19.0, 26.4)a
Alcohol, units/week 8.5 (14.3) 7.3 (11.1) 9.5 (13.6) 7.8 (10.6) −0.25 (−1.45, 1.24)a
Proportion reporting change in diet at 1 year, % – 57.2 (127/222) – 77.4 (175/226) 2.57 (1.70, 3.87)b
Smoking
Self-reported smokers, % 14.0 (31/222) 11.7 (26/222) 15.0 (34/227) 15.0 (34/227) 2.63 (0.76, 9.05)b
Medication adherence
Adhering to hypoglycaemic medication, %c – 81.2 (108/133) – 85.7 (132/154) 1.39 (0.74, 2.60)b
Adhering to general medication, %c 73.1 (147/201) 75.6 (161/213) 69.5 (148/213) 78.4 (174/222) 1.25 (0.79, 1.99)b
Values are mean (SD) unless stated
aModel residuals showed non-normality, which could not be resolved after log-transformation. Therefore, 95% CIs were calculated using the semi-
parametric bias corrected and accelerated bootstrap regression method (with 1,999 resamples)
b Results are expressed as ORs
cAdherence defined as a score of >23/25 on the MARS questionnaire
Diabetologia (2014) 57:1308–1319 1313
between-group differences. Self-reported adherence to general
medication increased in both groups from baseline to 1 year
follow-up. Medication adherence for both general and diabe-
tes medication was high in both groups at 1 year (defined as a
score of >23/25 on the MARS questionnaire), with no signif-
icant difference between groups. A significantly higher num-
ber of patients in the intervention than in the comparison
group reported that they had made positive changes to their
diet and physical activity in the preceding 12 months.
Clinical and biochemical measures
Table 4 shows the baseline and follow-up anthropometric,
clinical and biochemical measures. We observed small reduc-
tions in cardiovascular risk factors in both groups over 1 year.
The majority of between-group differences favoured the in-
tervention group but none achieved statistical significance.
Functional status, healthy utility, anxiety, well-being, quality
of life, treatment satisfaction and relational empathy
Participants in the intervention group reported significantly
higher levels of SF-36 physical functioning, SF-36 change in
health, health utility (EQ-5D) and satisfaction with diabetes
services than those in the comparison group (Table 5). There
was no intervention effect on the remaining SF-36 measures,
state anxiety, diabetes-specific and general well-being,
diabetes-related quality of life, diabetes treatment satisfaction
or relational empathy.
Beliefs about behavioural intentions, illness perceptions
and habit
Behavioural intentions were higher in the intervention than the
comparison group at 1 year, achieving statistical significance
for physical activity andmedication adherence (Table 6). Illness
perceptions, perceived behavioural control and behavioural
beliefs were similar in both groups at baseline and 1 year. In
addition, there were no differences between groups in the
strength of habit and diabetes knowledge levels at 1 year.
In total, 93% of participants attended the introductory and
initial three core-intervention sessions. Intervention group
participants reported feeling confident in using the skills they
had been taught (mean [SD] score 7.9 [1.7] on a scale of 0 to
10). Self-reported use of skills to increase physical activity and
to eat a lower-fat diet was relatively high, ranging from 62%
of participants who reported using prompts or reminders to
88% who reported setting achievable goals. Fewer
Table 4 Baseline and follow-up anthropometric, clinical and biochemical measures by study group and between-group differences in the ADDITION-
Plus trial
Measure Comparison group Intervention group Adjusted difference between
groups (95% CI)
Baseline 1 year Baseline 1 year
BMI, kg/m2 32.8 (5.7) 32.3 (5.7) 32.7 (5.3) 32.1 (5.2) −0.11 (−0.44, 0.22)
Waist circumference, cm 110.7 (15.1) 109.5 (15.2) 110.9 (12.4) 109.1 (11.8) −0.63 (−1.70, 0.44)
Body fat, % 42.1 (11.9) 41.8 (11.2) 42.8 (12.3) 42.0 (11.8) −0.30 (−1.72, 1.12)
Systolic BP, mmHg 134.4 (19.3) 128.3 (17.4) 138.2 (19.1) 132.1 (17.4) 1.76 (−0.92, 4.43)
Diastolic BP, mmHg 79.1 (10.9) 75.1 (9.8) 81.6 (10.0) 77.7 (8.8) 1.43 (−0.07, 2.92)
Cardiorespiratory fitness, ml/kg/min – 30.9 (9.5) – 30.3 (8.6) −0.61 (−2.63, 1.42)
HbA1c, % 7.01 (1.23) 6.67 (0.95) 7.23 (1.62) 6.66 (0.94) −0.09 (−0.25, 0.07)
HbA1c, mmol/mol 53.1 49.4 55.5 49.3
Total cholesterol, mmol/l 4.90 (1.16) 4.31 (0.86) 4.96 (0.98) 4.33 (0.91) −0.005 (−0.16, 0.15)
HDL-cholesterol, mmol/l 1.20 (0.35) 1.19 (0.32) 1.17 (0.35) 1.19 (0.31) 0.02 (−0.02, 0.05)
LDL-cholesterol, mmol/l 2.87 (0.99) 2.34 (0.76) 2.89 (0.91) 2.29 (0.77) −0.06 (−0.19, 0.08)
Log10 triacylglycerol, mmol/l 0.23 (0.24) 0.21 (0.23) 0.28 (0.22) 0.24 (0.24) −0.006 (−0.04, 0.03)
Log10 alanine aminotransferase 1.61 (0.19) 1.53 (0.18) 1.63 (0.21) 1.53 (0.19) −0.01 (−0.04, 0.02)
Microalbuminuria, %a 20.2% (43/213) 16.1% (35/217) 18.6% (41/220) 17.5% (39/223) 1.22 (0.68, 2.17)b
Rose angina questionnaire, % positive – 12.2% (27/222) – 12.0% (27/225) 0.98 (0.56, 1.74) b
Michigan neuropathy score 1.91 (1.67) 1.91 (1.88) 1.84 (1.61) 1.78 (1.71) −0.08 (−0.34, 0.18)
Log10 UKPDS 10 year CVD risk
c −0.63 (0.21) −0.68 (0.21) −0.62 (0.23) −0.68 (0.22) −0.02 (−0.04, 0.006)
Values are mean (SD) unless stated
a Albumin/creatinine ratio ≥2.5 (men), ≥3.5 (women)
b Results expressed as ORs
c Excluding n=53 reporting prior CVD
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participants reported using these skills to enhance medication
adherence, ranging from 50% who reported that they had
prepared for setbacks to 68% setting achievable goals. Skills
use was lowest among those participants who were trying to
stop smoking, with 26% recording or monitoring their prog-
ress and 45% reporting that they had set achievable goals.
Intervention participants rated their facilitators highly with a
mean response of 44 (SD 6.5, on a scale of 10–50).
Per protocol, subgroup and sensitivity analyses
Per protocol analyses of the primary outcome data replicated
our main results, except for the plasma vitamin C level for
which the increase over 12 months was slightly greater in the
comparison than in the intervention group (p=0.04). Our
conclusions were unaffected by the sensitivity analysis for
missing data. Similarly, there was no evidence that
intervention effects on the primary outcomes differed between
participants with screen-detected and recently diagnosed
diabetes.
Discussion
For patients with recently diagnosed diabetes offered intensive
treatment in primary care the additional input of a facilitator
from outside the practice delivering a theory-based multi-
behaviour intervention was not associated with significant im-
provements in objectively measured health behaviours. There
was no difference between trial groups in change from baseline
to 1 year in cardiovascular risk factors or self-reported health
behaviours. The intervention group reported higher levels of
SF-36 physical functioning as well as SF-36 change in health
status, health utility and satisfaction with diabetes services at
1 year, and greater changes in diet and activity over the year
Table 5 Functional status, health utility, anxiety, quality of life, well-being and satisfaction with treatment at 1 year by study group and between-group
differences in the ADDITION-Plus trial
Measurea Comparison group Intervention group Difference between groups (95% CI)b
SF-36
Physical functioning 73.3 (27.8) 79.2 (22.5) 5.89 (1.24, 10.85)
Role limitation, physical 71.7 (40.2) 76.0 (35.8) 4.32 (−3.06, 11.29)
Role limitation, emotional 84.4 (32.2) 80.7 (34.2) −3.69 (−9.98, 1.99)
Social functioning 83.6 (25.3) 85.1 (23.9) 1.51 (−2.93, 6.02)
Mental health 76.3 (19.4) 76.5 (17.3) 0.15 (−3.25, 3.32)
Energy/vitality 56.5 (24.0) 59.4 (20.8) 2.97 (−1.11, 7.21)
Pain 71.6 (27.3) 73.1 (25.2) 1.50 (−3.28, 6.37)
General health perception 59.7 (23.4) 61.2 (20.6) 1.46 (−2.98, 5.51)
Change in health 55.4 (20.9) 64.1 (22.7) 8.72 (4.57, 12.74)
Health utility
Self-reported general health (1 to 5) 2.94 (0.92) 3.11 (0.87) 0.19 (0.07, 0.31)c
EQ-5D (−0.3 to 1.0) 0.81 (0.26) 0.84 (0.20) 0.03 (0.003, 0.06)c
Anxiety
Spielberger State Anxiety (20 to 80) 30.5 (11.0) 29.6 (9.6) −0.85 (−2.56, 0.85)c
Quality of life and well-being
Quality of life (−9 to 9) 0.96 (1.28) 0.79 (1.05) −0.17 (−0.38, 0.06)
Diabetes-specific well-being (0 to 36) 28.2 (6.6) 28.8 (6.3) 0.61 (−0.70, 1.76)
General well-being (0 to 36) 26.4 (7.2) 26.9 (6.5) 0.47 (−0.80, 1.81)
Satisfaction with treatment, services and empathy
Diabetes treatment satisfaction (0 to 36) 30.0 (5.8) 30.6 (5.3) 0.59 (−0.41, 1.72)
General practitioner CARE measure (10 to 50) 39.1 (10.2) 40.3 (9.5) 1.23 (−0.64, 3.17)
Nurse CARE measure (10 to 50) 39.8 (9.8) 40.9 (9.1) 1.14 (−0.78, 2.89)
Satisfaction with diabetes services (1 to 4) 3.43 (0.79) 3.68 (0.56) 0.25 (0.13, 0.38)
Values are mean (SD) unless stated
a Values in parentheses represent the possible range for each measure
bModel residuals showed non-normality, which could not be resolved after log-transformation. Therefore, 95% CIs were calculated using the semi-
parametric bias corrected and accelerated bootstrap regression method (with 1,999 resamples)
c Difference between groups is adjusted for baseline values
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compared with the comparison group. However, there was no
intervention effect on the remaining SF-36 measures, state
anxiety, diabetes-specific and general well-being, diabetes-
related quality of life, diabetes treatment satisfaction or rela-
tional empathy. We found no evidence to support this external
behavioural facilitator model of care where the primary care
team delivers a well-organised and intensive treatment service.
Strengths and limitations
The study was carried out in primary care settings where most
of the care of individuals with recently diagnosed diabetes
takes place in the UK. General practice registers typically
cover 99% of all residents living in England [41], and nearly
half of the practices approached agreed to take part.
Generalisability to more deprived settings with greater ethnic
diversity may be limited in light of the non-random recruit-
ment of general practices from a single geographical region.
Internal validity was strong; participants were individually
randomised and groups were well matched for baseline char-
acteristics. Participant retention at 1 year was similarly high in
both trial groups. We used objective measurement of four key
behaviours affecting CVD risk, as well as measuring self-
reported behaviour, functional status and well-being. The
apparent effect on self-reported change in behaviours over
time highlights the need for caution in interpreting the results
of trials of behavioural interventions that rely on subjective
measures. Clinically important outcomes were measured
using standardised equipment and protocols, with trained staff
unaware of study group allocation.
The intervention was based on theory and evidence from
psychology to support change in behaviour [42], and included
a patient-centred approach to facilitating behaviour change,
which has been shown to be more effective than didactic
interventions in improving CVD risk factors [43, 44].
Quality-assured delivery was enabled by training, ongoing
supervision and protocols. The carefully characterised inter-
vention and the objective measurement of health behaviours
allowed us to isolate potential effects of the behavioural inter-
vention from other aspects of intensive general practice care.
Plasma drug and cotinine levels were available only for a
subset of participants and the timing of blood samples follow-
ing ingestion of tablets and other factors affecting plasma drug
levels were not standardised, which will have reduced the
precision of estimates. However, these issues did not differ
by study group and while the measure of adherence was less
precise, it was less prone to bias than self-report measures.
Objective measures of physical activity, smoking and medi-
cation adherence at baseline would have improved precision
and enabled us to assess change over time. However, such
detailed measurement might increase the salience and influ-
ence the behaviour of participants in both groups [45]. This is
Table 6 Baseline and follow-up behavioural beliefs, illness perceptions, strength of habit and diabetes knowledge by study group and between-group
differences in the ADDITION-Plus trial
Measuresa Comparison group Intervention group Adjusted difference between
groups (95% CI)
Baseline 1 year Baseline 1 year
Intention physical activity (1 to 5) 3.72 (0.83) 3.48 (0.79) 3.78 (0.74) 3.64 (0.81) 0.14 (0.007, 0.27)
Intention diet (1 to 5) 3.71 (0.79) 3.39 (0.84) 3.75 (0.76) 3.51 (0.81) 0.11 (−0.03, 0.25)
Intention medication adherence (1 to 5) 4.45 (0.56) 4.47 (0.60) 4.40 (0.67) 4.57 (0.58) 0.12 (0.01, 0.23)
Intention smoking (1 to 5) 3.16 (1.11) 3.12 (1.06) 3.20 (0.96) 3.20 (1.11) 0.003 (−0.32, 0.33)
Illness perception consequences (1 to 5) 2.90 (0.65) 2.88 (0.69) 2.89 (0.64) 2.95 (0.66) 0.08 (−0.03, 0.18)
Illness perception treatment control (1 to 5) 3.80 (0.52) 3.67 (0.55) 3.75 (0.48) 3.72 (0.52) 0.08 (−0.01, 0.16)
Perceived behavioural control physical activity (1 to 5) 3.72 (0.91) 3.51 (0.90) 3.82 (0.79) 3.67 (0.88) 0.12 (−0.03, 0.26)
Perceived behavioural control diet (1 to 5) 3.75 (0.83) 3.58 (0.85) 3.70 (0.89) 3.67 (0.87) 0.11 (−0.03, 0.26)
Perceived behavioural control medication (1 to 5) 4.49 (0.56) 4.47 (0.56) 4.47 (0.63) 4.56 (0.58) 0.10 (−0.002, 0.20)
Perceived behavioural control smoking (1 to 5) 2.70 (0.97) 2.90 (0.79) 2.79 (1.01) 2.91 (1.07) −0.07 (−0.44, 0.30)
Behavioural beliefs physical activity (1 to 5) 4.01 (0.75) 3.92 (0.64) 3.98 (0.62) 3.90 (0.72) −0.002 (−0.11, 0.11)
Behavioural beliefs diet (1 to 5) 3.83 (0.75) 3.75 (0.75) 3.90 (0.68) 3.81 (0.73) 0.02 (−0.10, 0.14)
Perceived effectiveness of lifestyle change (1 to 5) 3.95 (0.72) 3.82 (0.76) 3.91 (0.65) 3.84 (0.71) 0.05 (−0.08, 0.18)
Strength of PA habit change reported at 1 year (1 to 5) – 3.27 (0.72) – 3.41 (0.71) 0.14 (−0.05, 0.32)
Strength of diet habit change reported at 1 year (1 to 5) – 3.66 (0.55) – 3.64 (0.61) −0.02 (−0.15, 0.12)
Diabetes knowledge (self-administered questionnaire) (0 to 47) – 24.8 (9.18) – 25.8 (8.53) 0.92 (−0.72, 2.57)
Values are mean (SD) unless stated
a Values in parentheses represent the possible range for each measure
PA, physical activity
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likely to be more relevant to physical activity than to the other
health behaviours assessed via blood samples.
Understanding the results
There may have been limited scope for additional benefit
among ADDITION-Plus patients, who were already receiving
intensive treatment, including theory-based educational mate-
rials and lifestyle advice on all the target behaviours by the
primary care team. In addition, there were improvements from
baseline in plasma vitamin C levels, self-reported diet and
physical activity and cardiovascular risk factors in both study
groups, further limiting potential change. The absence of an
intervention effect on health behaviours was unlikely to be due
to failure to deliver the programme. Attendance at intervention
sessions, self-reported use of skills to improve lifestyle behav-
iours and levels of satisfaction with the programme were all
high. Facilitators met monthly to discuss intervention delivery
and listened to tape recordings of their sessions. They also
received ongoing supervision and support from a clinical psy-
chologist. The intervention was associated with stronger inten-
tions to change physical activity and medication adherence at
follow-up. We targeted mediators of behaviour change and
included behaviour change techniques from a range of theories.
However, the evidence that any of the commonly used theories
predict changes in objectively assessed health behaviours is
limited. Behaviour change might be enhanced by focusing on
fewer behaviours and being more directive in selecting which
ones to focus on. Targeting dietary change and physical activity
sequentially might be less effective than targeting them simul-
taneously, but more evidence is needed [46]. Increasing the
intensity of the training or of intervention delivery could have
enhanced the opportunity to change behaviour, but may not be
feasible in routine practice. Facilitator-led care focusing on
behaviour change might add value in settings where primary
care based intensive treatment is not feasible or effective.
We recorded moderate effects of the intervention on mea-
sures of self-reported health status, health utility and physical
function. These positive effects occurred independently of any
change in objectively measured health behaviours, suggesting
a mechanism independent of behaviour change. Other trials
have also shown that interventions can improve patient-
reported outcomes such as well-being but not behaviour or
clinical endpoints [33, 47]. It is not clear whether the improve-
ments were related to the supportive alliances formed with
lifestyle facilitators or whether the effect was mediated by a
feeling of false reassurance from participating in the interven-
tion [48]. Regardless of the mechanism, self-reported health is
an independent predictor of mortality [49]. These improve-
ments warrant further examination, particularly if they persist
over the long term when intervention support is withdrawn
and can be achieved with a less intensive intervention. Five-
year follow-up of the trial cohort is planned.
Recent attempts to promote behaviour change in individuals
soon after the diagnosis of diabetes have had mixed effects. In
the Diabetes Education and Self-Management for Ongoing
and Newly Diagnosed Diabetes (DESMOND) trial (ISRCT
N17844016), 824 newly diagnosed patients were cluster
randomised to receive either a 6 h structured group-education
programme focused on behaviour change or usual care (com-
parison group) [50]. The DESMOND trial participants had a
mean age of 60 years, included more men than women (55%),
had a mean BMI of approximately 32 kg/m2 and were, there-
fore, broadly similar to ADDITION-Plus participants. The
intervention was based on similar theories of learning used in
the ADDITION-Plus trial and focused on lifestyle factors such
as food choice and physical activity. Compared with the con-
trol group, the intervention group achieved greater improve-
ments in weight loss and smoking cessation and positive
improvements in belief about illness, but no difference in
HbA1c levels after 1 year. Self-reported physical activity levels
were higher in the intervention than in the comparison group at
all time points, but were not significantly different at 1 year.
There was no objective measurement of behaviour change in
this trial cohort and it was difficult to elucidate exactly which
components of the intervention were associated with the ob-
served improvements. Further, the DESMOND control group
was different from our comparison group, where individuals
were already receiving intensive treatment for diabetes.
In the Early ACTID trial, 593 recently diagnosed patients
with a mean age of 60 years were randomised to receive usual
care (control group), an intensive diet intervention (6.5 h of
individual counselling by a dietitian/nurse over 1 year) or an
intensive diet intervention plus a pedometer-based activity
programme [7]. After 12 months, there were significant im-
provements in glycaemic control, insulin resistance and body
weight in both intervention groups compared with the control
group; however, the addition of the activity intervention con-
ferred no extra benefit. Accelerometry data indicated that
individuals in the diet and activity group increased their phys-
ical activity significantly more than those in the other two
groups. However, the lack of measurement of dietary change
or any other health behaviour again makes it difficult to
explain the beneficial effects observed in this trial. Other
studies examining behavioural change in type 2 diabetes
patients tend to be small, of shorter duration and to focus on
individuals later in the disease trajectory. No published trial to
date captures objective measurement of four key health be-
haviours in recently diagnosed patients.
Conclusion
A facilitator-led, individually tailored multiple behaviour
change intervention over 1 year did not improve objectively
measured health behaviours or cardiovascular risk factors
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among people with recently diagnosed type 2 diabetes receiv-
ing intensive treatment in UK primary care. Effects on self-
reported changes in diet and physical activity were not con-
firmed by objective data, highlighting the need for caution in
interpreting trials of behavioural interventions that rely on
subjective measures. Enabling primary care teams to deliver
a well-organised intensive treatment service to newly diag-
nosed patients should remain a priority for policymakers and
commissioners.
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